Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma-Reference-Cited by-同舟云学术

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Published:2024-05-20 Issue:10 Volume:8 Page:2400-2404
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Zinzani Pier Luigi¹^ORCID,Salles Gilles²^ORCID,Moskowitz Alison J.²,Santoro Armando³^ORCID,Mehta Amitkumar⁴^ORCID,Barr Paul M.⁵^ORCID,Mehta-Shah Neha⁶^ORCID,Collins Graham P.⁷,Ansell Stephen M.⁸,Brody Joshua D.⁹^ORCID,Domingo-Domenech Eva¹⁰^ORCID,Johnson Nathalie A.¹¹,Cunningham David¹²^ORCID,Ferrari Silvia¹³^ORCID,Lisano Julie¹⁴,Krajewski Jennifer¹⁵,Wen Rachael¹⁵,Akyol Alev¹⁵,Crowe Russell¹⁵,Savage Kerry J.¹⁶^ORCID

Affiliation:

1. 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” University of Bologna, Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

2. 2Memorial Sloan Kettering Cancer Center, New York, NY

3. 3Humanitas University, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy

4. 4School of Medicine, University of Alabama at Birmingham, Birmingham, AL

5. 5Department of Medicine, University of Rochester, Rochester, NY

6. 6Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO

7. 7Department of Hematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, United Kingdom

8. 8Division of Hematology, Mayo Clinic, Rochester, MN

9. 9Icahn School of Medicine at Mount Sinai, New York, NY

10. 10Clinical Hematology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

11. 11Department of Medicine & Oncology, Jewish General Hospital, Montreal, QC, Canada

12. 12Royal Marsden Hospital, London, United Kingdom

13. 13Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

14. 14Seagen Inc, Bothell, WA

15. 15Bristol Myers Squibb, Princeton, NJ

16. 16BC Cancer, Vancouver, BC, Canada

Publisher

American Society of Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/8/10/2400/2226414/blooda_adv-2023-011030-main.pdf

Reference23 articles.

1. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors;Mak;J Clin Oncol,2013

2. Treatment patterns and outcomes of relapsed/refractory peripheral T-cell lymphoma (RR-PTCL) patients treated in the community oncology setting;Nabhan;Blood,2018

3. Retrospective analysis of 118 patients with cutaneous T-cell lymphomas: a single-center experience;Polgarova;Front Oncol,2022

4. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders;Wilcox;Blood,2009

5. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels;Bossard;Blood,2014